HealthEquity (HQY) Stock Price, News & Analysis

Company Overview

HealthEquity, Inc. (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions. In 2020, the company expanded its suite of offerings through the acquisition of WageWorks, broadening its reach into commuter and lifestyle benefits. HealthEquity’s digital platform features online tools, mobile applications and customer support to simplify enrollment, claims processing and regulatory compliance for plan sponsors and participants.

HealthEquity is led by Chief Executive Officer Jon Kessler, supported by founder and Executive Chairman Stephen Nee. Under their stewardship, the company has focused on product innovation, strategic partnerships and operational efficiency to deliver scalable benefits solutions. HealthEquity continues to invest in technology enhancements and integrations aimed at empowering consumers to take greater control over their healthcare finances.

Key Stats

• Today's Range: $87.94 to $89.50
• 50-Day Range: $87.42 to $104.88
• 52-Week Range: $73.84 to $116.65
• Volume: 1.52 million shs
• Average Volume: 940,453 shs
• Market Capitalization: $7.72 billion
• P/E Ratio: 65.20
• Dividend Yield: N/A
• Price Target: $117.82
• Consensus Rating: Buy

HealthEquity Stock Analysis - MarketRank™

HealthEquity scored higher than 92% of companies evaluated by MarketBeat, and ranked 151st out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

HealthEquity has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

HealthEquity has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 22.41%

Earnings Growth

Earnings for HealthEquity are expected to grow by 22.41% in the coming year, from $2.32 to $2.84 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of HealthEquity is 65.20, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 270.81.

Price to Earnings Ratio vs. Sector

The P/E ratio of HealthEquity is 65.20, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 83.19.

Price to Earnings Growth Ratio

HealthEquity has a PEG Ratio of 1.37. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

HealthEquity has a P/B Ratio of 3.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.64% of the float of HealthEquity has been sold short.

Short Interest Ratio / Days to Cover

HealthEquity has a short interest ratio ("days to cover") of 4.7.

Change versus previous month

Short interest in HealthEquity has recently decreased by 11.60%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

HealthEquity does not currently pay a dividend.

Dividend Growth

HealthEquity does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.64% of the float of HealthEquity has been sold short.

Short Interest Ratio / Days to Cover

HealthEquity has a short interest ratio ("days to cover") of 4.7.

Change versus previous month

Short interest in HealthEquity has recently decreased by 11.60%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.28

News Sentiment

HealthEquity has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.05 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 29 news articles for HealthEquity this week, compared to 15 articles on an average week.

Search Interest

3 people have searched for HQY on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, HealthEquity insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $32,705,007.00 in company stock.

Percentage Held by Insiders

Only 1.50% of the stock of HealthEquity is held by insiders.

Percentage Held by Institutions

99.55% of the stock of HealthEquity is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

HQY Stock Analysis - Frequently Asked Questions

How have HQY shares performed this year?

HealthEquity's stock was trading at $95.95 at the beginning of the year. Since then, HQY stock has decreased by 6.9% and is now trading at $89.33.

How were HealthEquity's earnings last quarter?

HealthEquity, Inc. (NASDAQ:HQY) posted its earnings results on Tuesday, June, 3rd. The company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.81 by $0.16. The company earned $330.80 million during the quarter, compared to analyst estimates of $322.25 million. HealthEquity had a net margin of 9.80% and a trailing twelve-month return on equity of 11.01%.
Read the conference call transcript.

Who are HealthEquity's major shareholders?

HealthEquity's top institutional investors include Wasatch Advisors LP (7.06%), State Street Corp (3.68%), Invesco Ltd. (2.74%) and Geode Capital Management LLC (2.48%). Insiders that own company stock include Jon Kessler, Ian Sacks, Stephen Neeleman, Robert W Selander, Elimelech Rosner, Tyson D Murdock, Michael Henry Fiore, Delano Ladd, Larry L Trittschuh, Evelyn S Dilsaver, Stuart B Parker, Gayle Furgurson Wellborn, Debra Charlotte Mccowan and Frank Corvino.
View institutional ownership trends.

How do I buy shares of HealthEquity?

Shares of HQY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of HealthEquity own?

Based on aggregate information from My MarketBeat watchlists, some other companies that HealthEquity investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and Adobe (ADBE).

Company Calendar

• Last Earnings: 6/03/2025
• Today: 8/30/2025
• Next Earnings (Estimated): 9/02/2025
• Fiscal Year End: 1/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:HQY
• CIK: 1428336
• Web: www.healthequity.com
• Phone: (801) 727-1000
• Fax: 801-727-1005
• Employees: 3,120
• Year Founded: N/A

Price Target and Rating

• Average Price Target for HealthEquity: $117.82
• High Price Target: $130.00
• Low Price Target: $100.00
• Potential Upside/Downside: +31.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.37
• Trailing P/E Ratio: 65.20
• Forward P/E Ratio: 38.50
• P/E Growth: 1.37
• Net Income: $96.70 million
• Net Margins: 9.80%
• Pretax Margin: 12.37%
• Return on Equity: 11.01%
• Return on Assets: 6.77%

Debt

• Debt-to-Equity Ratio: 0.50
• Current Ratio: 4.06
• Quick Ratio: 4.06

Sales & Book Value

• Annual Sales: $1.20 billion
• Price / Sales: 6.44
• Cash Flow: $4.31 per share
• Price / Cash Flow: 20.71
• Book Value: $24.40 per share
• Price / Book: 3.66

Miscellaneous

• Outstanding Shares: 86,470,000
• Free Float: 85,178,000
• Market Cap: $7.72 billion
• Optionable: Optionable
• Beta: 0.54